[SCHEDULE 13G] PMV Pharmaceuticals, Inc. SEC Filing

Rhea-AI Filing Summary

Tang Capital group reports collective ownership of 4,720,357 shares of PMV Pharmaceuticals common stock, representing 8.9% of the outstanding class. The filing discloses that Tang Capital Management, LLC, Kevin Tang, Tang Capital Partners, LP and Tang Capital Partners International, LP share voting and dispositive power over these shares. The ownership figures are based on 52,990,864 shares outstanding as of August 6, 2025, per the issuer's quarterly report.

The statement clarifies that the reported securities were not acquired to change or influence control of PMV and lists office addresses and organizational domiciles for the reporting entities and individuals.

Positive

• Disclosed a clear, material stake of 4,720,357 shares (8.9%) in PMV Pharmaceuticals, meeting SEC transparency requirements
• Filing identifies shared voting and dispositive power among Tang entities and Kevin Tang, clarifying the governance relationships
• Percentage basis provided (52,990,864 shares outstanding as of August 6, 2025) for transparent calculation

Negative

• None.

Insights

Financial Analyst

TL;DR: Tang Capital disclosed an 8.9% stake in PMV, a meaningful 5%+ holding that signals a sizable passive equity position.

The Schedule 13G shows the Tang group collectively owns 4,720,357 shares (8.9% of the class), with shared voting and dispositive power—no sole control. For investors, a >5% passive disclosure is material because it identifies a significant shareholder group, but the filing asserts the stake is not intended to influence control. The filing cites 52,990,864 shares outstanding for the percentage calculation and provides entity domiciles and addresses, supporting transparency of ownership and relationships among reporting persons.

Corporate Governance Expert

TL;DR: This is a routine 13G disclosure showing coordinated ownership but no expressed intent to influence control.

The document documents shared voting/dispositive power among TCM, TCP, TCPI and Kevin Tang, consistent with a group holding reporting requirement. The certification states the shares were not acquired to change or influence issuer control and references nomination-related activity exception. Signatures from the related entities and Kevin Tang provide the required attestations. No group dissolution, additional arrangements, or control plans are disclosed.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

PMV Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, par value $0.00001 per share

(Title of Class of Securities)

69353Y103

(CUSIP Number)

09/16/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 69353Y103

1

Names of Reporting Persons

TANG CAPITAL MANAGEMENT, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 4,720,357.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 4,720,357.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,720,357.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.9 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: Tang Capital Management, LLC ("TCM") shares voting and dispositive power over such shares with Tang Capital Partners, LP ("TCP"), Tang Capital Partners International, LP ("TCPI") and Kevin Tang. The percentages used herein are based on 52,990,864 shares of Common Stock outstanding as of August 6, 2025, as set forth in the Quarterly Report filed on Form 10-Q that was filed with the Securities and Exchange Commission on August 7, 2025.

SCHEDULE 13G

CUSIP No. 69353Y103

1

Names of Reporting Persons

KEVIN TANG

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 4,720,357.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 4,720,357.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,720,357.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.9 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: Kevin Tang shares voting and dispositive power over such shares with TCP, TCPI and TCM.

SCHEDULE 13G

CUSIP No. 69353Y103

1

Names of Reporting Persons

TANG CAPITAL PARTNERS, LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,654,728.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,654,728.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,654,728.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.0 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: TCP shares voting and dispositive power over such shares with TCM and Kevin Tang.

SCHEDULE 13G

CUSIP No. 69353Y103

1

Names of Reporting Persons

TANG CAPITAL PARTNERS INTERNATIONAL, LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,065,629.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,065,629.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,065,629.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.9 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: TCPI shares voting and dispositive power over such shares with TCM and Kevin Tang.

SCHEDULE 13G

CUSIP No. 69353Y103

1

Names of Reporting Persons

TANG CAPITAL PARTNERS III, INC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

NEVADA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.0 %

12

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

CUSIP No. 69353Y103

1

Names of Reporting Persons

TANG CAPITAL PARTNERS IV, INC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

NEVADA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.0 %

12

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: PMV Pharmaceuticals, Inc.
(b)	Address of issuer's principal executive offices: 400 Alexander Park Drive, Suite 301, Princeton, NJ, 08540
Item 2.
(a)	Name of person filing: This Statement on Schedule 13G (this "Statement") is filed by TCM, the general partner of TCP and TCPI; Kevin Tang, the manager of TCM and Chief Executive Officer of Tang Capital Partners III, Inc. ("TCP III") and Tang Capital Partners IV, Inc. ("TCP IV"); TCP; TCPI; TCP III; and TCP IV.
(b)	Address or principal business office or, if none, residence: The address of TCM, Kevin Tang, TCP and TCPI is 4747 Executive Drive, Suite 210, San Diego, CA 92121. The address of TCP III and TCP IV is 400 S. 4th Street, 3rd Floor, Las Vegas, NV 89101.
(c)	Citizenship: TCM is a Delaware limited liability company. Mr. Tang is a United States citizen. TCP and TCPI are Delaware limited partnerships. TCP III and TCP IV are Nevada corporations that are indirectly wholly owned by TCP.
(d)	Title of class of securities: Common Stock, par value $0.00001 per share
(e)	CUSIP No.: 69353Y103
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 4,720,357
(b)	Percent of class: 8.9 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0 shares
	(ii) Shared power to vote or to direct the vote: 4,720,357 shares
	(iii) Sole power to dispose or to direct the disposition of: 0 shares
	(iv) Shared power to dispose or to direct the disposition of: 4,720,357 shares
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

TANG CAPITAL MANAGEMENT, LLC

Signature:	/s/ Kevin Tang
Name/Title:	Manager
Date:	09/23/2025

KEVIN TANG

Signature:	/s/ Kevin Tang
Name/Title:	Self
Date:	09/23/2025

TANG CAPITAL PARTNERS, LP

Signature:	/s/ Kevin Tang
Name/Title:	Manager, Tang Capital Management, LLC, General Partner
Date:	09/23/2025

TANG CAPITAL PARTNERS INTERNATIONAL, LP

Signature:	/s/ Kevin Tang
Name/Title:	Manager, Tang Capital Management, LLC, General Partner
Date:	09/23/2025

TANG CAPITAL PARTNERS III, INC

Signature:	/s/ Kevin Tang
Name/Title:	Chief Executive Officer
Date:	09/23/2025

TANG CAPITAL PARTNERS IV, INC

Signature:	/s/ Kevin Tang
Name/Title:	Chief Executive Officer
Date:	09/23/2025

FAQ

How many PMVP shares does Tang Capital report owning?

The filing reports 4,720,357 shares, representing 8.9% of PMV Pharmaceuticals' common stock.

Does the Schedule 13G indicate Tang Capital intends to influence control of PMV (PMVP)?

No. The certification states the securities were not acquired and are not held for the purpose of changing or influencing control of the issuer.

Which entities share voting and dispositive power over the reported shares?

Tang Capital Management, LLC, Tang Capital Partners, LP, Tang Capital Partners International, LP and Kevin Tang share voting and dispositive power.

What outstanding share count is used to calculate the 8.9% figure?

The percentage is based on 52,990,864 shares of common stock outstanding as of August 6, 2025, per the issuer's quarterly report.

Who signed and certified the Schedule 13G for Tang Capital?

The filing is signed by Kevin Tang on behalf of Tang Capital Management, Tang Capital Partners, Tang Capital Partners International, and related entities, dated 09/23/2025.